Effect of Febuxostat-assisted celecoxib therapy on the efficacy,pain and inflammatory factors of hyperuricemic gout patients
Objective:To investigate the clinical effect of febuxostat assisted celecoxib in the treatment of hyperuricemia gout and its effect on pain and inflammatory factors.Methods:78 patients with hyperuricemia gout admitted to our hospital from March 2021 to March 2023 were selected as the study objects.The patients were randomly divided into control group and study group,39 cases in each group.The control group was treated with celecoxib capsule;the study group was treated with febuxostat tablets and celecoxib capsules.After 7 days of treatment,the clinical efficacy,pain degree,inflammatory factor level and adverse reactions of the two groups were analyzed and compared.Results:Compared with the control group,the total effective rate of the study group was significantly increased(P<0.05).After treatment,the visual analogue scale(VAS)score of both groups was significantly lower than that before treatment,and the VAS score of the study group was significantly lower than that of the control group(P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β),C-reactive protein(CRP)and erythrocyte sedimentation Rate(ESR)in both groups were significantly lower than those of the treatment.The levels of TNF-α,IL-1β,CRP and ESR in the study group were significantly lower than those in the control group(P<0.05).Conclusion:Febuxostat assisted celecoxib in the treatment of hyperuricemia gout,which can improve the clinical effect,relieve pain and improve the level of inflammatory factors,with high safety.
万方数据
维普
